Safety and Pharmacokinetics of Intravenous 10-1074 and VRC01LS in Young Children.

Journal Article (Journal Article)

BACKGROUND: Broadly neutralizing monoclonal antibodies (bNAbs) suppress HIV-1 RNA and may deplete residual viral reservoirs. We evaluated the safety and pharmacokinetics (PK) of dual intravenous VRC01LS and 10-1074 in very early-treated children with HIV-1 on suppressive antiretroviral treatment (ART). SETTING: Botswana. METHODS: Children with HIV-1 (median age 3.1 years) on ART from <7 days old were enrolled. In phase A, 6 children received 10-1074 (30 mg/kg at day 0, 28, and 56) and 6 children received VRC01LS (30 mg/kg at day 0, 10 mg/kg at days 28 and 56) by intravenous infusion. In phase B, 6 children received the 2 bNAbs combined (with higher VRC01LS maintenance dose, 15 mg/kg) every 4 weeks for 32 weeks with PK evaluations over 8 weeks. Population PK models were developed to predict steady-state concentrations. RESULTS: BNAb infusions were well tolerated. There were no infusion reactions nor any bNAb-related grade 3 or 4 events. The median (range) first dose Cmax and trough (day 28) combined from both phases were 1405 (876-1999) μg/mL and 133 (84-319) μg/mL for 10-1074 and 776 (559-846) μg/mL and 230 (158-294) μg/mL for VRC01LS. No large differences in bNAb clearances were observed when given in combination. The estimated VRC01LS half-life was shorter than in adults. Predicted steady-state troughs [median (90% prediction interval)] were 261 (95-565) and 266 (191-366) μg/mL for 10-1074 and VRC01LS, respectively, when given in combination. CONCLUSIONS: 10-1074 and VRC01LS were safe and well-tolerated among children receiving ART. Troughs exceeded minimal targets with every 4-week administration of 10-1074 at 30 mg/kg and VRC01LS at 15 mg/kg.

Full Text

Duke Authors

Cited Authors

  • Capparelli, EV; Ajibola, G; Maswabi, K; Holme, MP; Bennett, K; Powis, KM; Moyo, S; Mohammed, T; Maphorisa, C; Hughes, MD; Seaton, KE; Tomaras, GD; Mosher, S; Taylor, A; O'Connell, S; Narpala, S; Mcdermott, A; Caskey, M; Gama, L; Lockman, S; Jean-Philippe, P; Makhema, J; Kuritzkes, DR; Lichterfeld, M; Shapiro, RL; Tatelo Study Team,

Published Date

  • October 1, 2022

Published In

Volume / Issue

  • 91 / 2

Start / End Page

  • 182 - 188

PubMed ID

  • 36094485

Electronic International Standard Serial Number (EISSN)

  • 1944-7884

Digital Object Identifier (DOI)

  • 10.1097/QAI.0000000000003033


  • eng

Conference Location

  • United States